文献速递糖尿病

全球糖尿病研究中的种族、族裔与血统:应对复杂性以推进公平与科学诚信

Race, ethnicity and ancestry in global diabetes research: grappling with complexity to advance equity and scientific integrity - a narrative review and viewpoint.
PubMed 文献 · Diabetologia · 2025-08-07

本文为叙述性综述与观点文章,讨论全球糖尿病研究中种族、族裔与血统术语的定义与使用,指出仅以人群归属判断风险或干预反应不充分,应识别遗传、环境、社会文化与政策等因果因素,并强调纳入多样人群与多学科方法对减轻全球糖尿病负担至关重要。

要点

  • 人群归属本身不决定糖尿病风险或干预反应,应识别遗传、环境、社会文化与政策等因果因素。
  • 常用糖尿病药物反应按人群分组差异证据有限,但性别、年龄与肥胖等特征影响降糖药效果。
  • 糖尿病研究应纳入多样人群并明确人群定义,以提升科学诚信与健康公平。

核心结论

  • 人群归属本身不决定糖尿病风险或干预反应,因果因素为遗传、环境、社会文化与政策的交汇。
  • 纳入多样人群并结合多学科方法,对应对全球糖尿病负担至关重要。

研究设计与样本

  • 叙述性综述与观点文章,未报告系统检索范围或样本量。

主要发现

  • 全球糖尿病负担不成比例地影响非欧洲血统人群,多数居住于低中收入国家。
  • 主要来源于欧洲起源人群的知识可能不易迁移至其他人群。
  • 常见糖尿病为多基因性,人群 unlikely 携带解释显著风险的单个基因。
  • 影响生活方式与生物学的环境变化可改变糖尿病风险并提供有效干预机会。
  • 遗传变异与不良事件相关,但人群分组有时并非此类变异的有效代理。

关键数值与推荐

  • 对多数糖尿病药物,鲜有证据表明药物反应性按人群分组存在实质性差异。
  • 性别、年龄与肥胖等其他人群特征似可改变降糖药物有效性,处方时应考虑。

临床怎么用

  • 处方降糖药物时应考虑性别、年龄与肥胖等特征,而非仅依据人群分组。
  • 糖尿病研究应纳入多样人群并明确人群定义,以提升证据可迁移性与公平性。

局限性

  • 本文为叙述性综述与观点文章,未报告系统检索策略或定量合并分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The global burden of diabetes-across major forms such as type 2 diabetes, type 1 diabetes and gestational diabetes mellitus-disproportionately affects people of non-European ancestry, the majority of whom live in low- and middle-income countries. The heterogeneity of diabetes risks and phenotypes indicates that knowledge derived principally from European-origin populations may not be readily transferable to other groups. In this review our aim is to enhance the quality of diabetes research by championing the inclusion of diverse populations, ensuring clarity of population definition and encouraging exploration of population differences. We review the terminology used to define populations and make recommendations on the use of these terms. We argue that population membership by itself does not determine risks or response to intervention; rather, it is the confluence of genetic, environmental, sociocultural and policy factors that are causal and should be identified. We note that, while common diabetes forms are polygenic and populations are unlikely to harbour single genes that account for significant risk, environmental change that impacts lifestyle and biology demonstrably alters diabetes risk and provides opportunities for effective intervention. Similarly, while genetic variants are associated with adverse events, population group membership may sometimes not be a valid proxy for such variants, which has implications for healthcare equity. For most drugs used in diabetes there is little evidence that drug responsiveness materially differs by population grouping, although it is only recently that well-designed studies have been performed. In contrast, other population characteristics, such as sex, age and obesity, appear to alter glucose-lowering drug effectiveness and should be considered when prescribing. Inclusion of diverse populations in diabetes research, combined with a multidisciplinary approach, is essential if we are to combat the global burden of diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Chaturvedi N, Voight BF, Wells JC, et al. Race, ethnicity and ancestry in global diabetes research: grappling with complexity to advance equity and scientific integrity - a narrative review and viewpoint. Diabetologia. 2025. PMID: 40770495. doi:10.1007/s00125-025-06516-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。